This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Here's Why You Should Add Altimmune Stock to Your Portfolio Now
by Zacks Equity Research
ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.
ALTNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVPositive Net Change
biotechs
Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails
by Zacks Equity Research
DNLI sinks after BIIB122 failed a mid-stage Parkinson's study, prompting Denali and Biogen to halt development in idiopathic cases.
SNYNegative Net Change BIIBPositive Net Change DNLINegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will the IG Market Challenges Affect ADMA Biologics Prospects in 2026?
by Ekta Bagri
ADMA cuts 2026 guidance after weak Bivigam sales and IG market pressure weigh on revenues amid rising competition and order volatility.
GRFSNegative Net Change ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
by Ahan Chakraborty
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
by Ahan Chakraborty
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
by Ahan Chakraborty
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
SRPTNegative Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
by Zacks Equity Research
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why You Should Add SMMT Stock to Your Portfolio Now
by Zacks Equity Research
Summit Therapeutics advances ivonescimab with late-stage NSCLC and CRC studies, with FDA review underway and new partnerships expanding its oncology reach.
GSKNegative Net Change MRKPositive Net Change SMMTNegative Net Change
biotechs
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
by Zacks Equity Research
BMRN's shares rise after Voxzogo hits the main goal in a late-stage hypochondroplasia study, supporting planned FDA filings in 2026.
BMRNNegative Net Change ASNDNegative Net Change BBIONegative Net Change
biotechs medical
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
BMYNegative Net Change MRKPositive Net Change AGENNegative Net Change
biotechs medical pharmaceuticals